Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Next Previous
Search
Trial Profile

A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Biosplice Therapeutics; Samumed

    • Most Recent Events

    • 22 Aug 2020 Results of pooled analysis of three trials presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 06 Jun 2020 Results (n=848) of pooled analysis of three studies (NCT02095548; NCT03122860 & NCT02536833) assessing early-phase lorecivivint clinical data for safety, including bone health-related adverse events presented at the 21st Annual Congress of the European League Against Rheumatism.
    • 13 Nov 2019 Results of pooled analysis from NCT02095548, NCT03122860 and NCT02536833 studies, presented in a Samumed media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top